Hepatocellular carcinoma among patients with chronic hepatitis B in the indeterminate phase.

57 Although the study was not powered to show a difference in necroinflammation, an overall trend of lower progression of necroinflammation (defined as increase of ≥2 points using the Knodell score) was observed in the treated group, where 5 (7%) progressed compared to 12 (16%) in the placebo group (RR = 0.42; 95% CI: 0.15–1.12; p = .084). 57 Among treated patients, 2/79 (3%) experienced ac

also in 4,871 other papers